Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Benitec Biopharma Inc.

NASDAQ: BNTC · Life Sciences · 7 alerts · CIK 1808898

Share price
$8.54Close, Nov 16
Market cap
$298M
Shares outstanding
34.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Benitec Biopharma Inc. filings on SEC EDGAR ↗

8:23 AM ET 10-Q
Financial Results

Benitec Biopharma Q1 2026 Results: Net Loss of $12.9M, Loss Widens

Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million in the prior year period, primarily driven by a significant increase in research and development expenses for their BB-301 program. The company maintained a strong liquidity position with $176.4 million in cash and cash equivalents to fund ongoing clinical development.

Key figure
Net loss $12.9M
8:03 AM ET 8-K
Financial Results

Benitec Biopharma Financial Results

Benitec Biopharma reported financial results for its first fiscal quarter ended September 30, 2026, and announced a change in its fiscal year-end from June 30 to December 31. The company highlighted a 100% responder rate in its ongoing Phase 1b/2a study of BB-301 for OPMD and confirmed it remains on track to begin a pivotal trial in mid-2027.

Term
Q1 2027

“The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”

Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.